Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Marching ahead - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jan 11, 2002

    Ranbaxy: Marching ahead

    Recently, Ranbaxy announced that its US subsidiaries have achieved the crucial US$ 100 m revenue mark. The full year results for the company are just round the corner (29th Jan'02) and we expect the company to cross US$ 600 m revenue mark on a consolidated basis for the current year. The company seems well on its way to achieve its revenue target of US$ 1 bn by 2004 end.

    (Rs m) 4QFY01 4QFY02E % Change FY01 FY02E % Change
    Sales 4,785 5,646 18.0% 17,418 20,631 18.4%
    Other Income 268 25 -90.7% 485 321 -33.8%
    Expenditure 4,401 4,664 6.0% 15,446 17,559 13.7%
    Operating Profit (EBDIT) 384 982 155.8% 1,972 3,072 55.8%
    Operating Profit Margin (%) 8.0% 17.4%   11.3% 14.9%  
    Interest 0 204 0 691
    Depreciation 129 130 0.8% 501 516 3.0%
    Profit before Tax 523 673 28.8% 1,956 2,186 11.8%
    Extraordinary Income/Provisions 0 0 0 960
    Provisions/Contigencies 0 0 0 (300)
    Tax 40 71 76.8% 147 286 94.4%
    Profit after Tax/(Loss) 483 603 24.8% 1,809 2,561 41.6%
    Net profit margin (%) 10.1% 10.7%   10.4% 12.4%  
    No. of Shares (eoy) (m) 116 116   116 116  
    Diluted Earnings per share* 16.7 20.8   15.6 22.1  

    (*- annualised)

    On a standalone basis, we expect the company to record sales growth of around 18% for FY02, with 360 basis points rise in operating margins. The spurt is expected to be on the back of ramp up in last two quarters. Operating margins for the last quarter (4QFY02) are expected to jump by 940 basis points on the back of rising contribution from high margin generic exports. We expect the company to register a PBT (before extra-ordinary/one time items) of Rs 2.1 bn, a growth of around 12%. Net profit is however, likely to register a faster growth rate due to extra-ordinary income.

    The year would also be marked with considerable presence of one time/ extra-ordinary charges/ income in the company's financials. In the first quarter of FY01, Ranbaxy received Rs 233 m (US$ 5 m) as technology licensing income from Bayer AG. Again in the third quarter, there was an extra-ordinary income of Rs 727 m on account of profit from sale of its stake in joint venture with Eli Lilly. The company also booked Rs 300 m loss on account of its stock market activity through its subsidiary, Vidyut Investments. There was a considerable drop in other income due to discontinuance of its stock market activity.

    Ranbaxy has ramped up its product approvals in last few months for the International markets. The latest one being generic manufacturing and marketing approval for all combinations of Lisinopril drug, which is a multi-billion cardiovascular molecule. The company now has a basket of 44 products for the US markets, far ahead of any other Indian generic company. The company's targeted penetration in Germany, Brazil and UK also seems to be working well.

    Export strategy of the company.

    With expected global sales in excess of US$ 600 m and export presence in 50 countries across the globe, the company has already achieved critical mass in the International pharma business. If Ranbaxy is successful in its ambitious foray into the global markets, it would be truly be a multinational giant from India. At the current market price of Rs 735, the stock trades at a P/e of 33 x its FY02E earnings on a standalone basis.



    Equitymaster requests your view! Post a comment on "Ranbaxy: Marching ahead". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks